• Presented at the 2024 ASCO Genitourinary Cancers Symposium, PRO-WAVE1 Research Results Showcase Opportunity to Operationalize the Patient-Provider Connection to Better Manage Cancer Care

  • Rich Data Includes Exceptional HCP Report of Overall Platform Impact, Combined with High Patient App Acceptance, Perceived Value, and Patients Reporting Feeling Less Anxious About Their Treatment Experience

San Francisco, CA – Treatment Technologies & Insights (TTI), a digital health insights and real world data company that developed the Wave Health platform, including the #1 ranked ePRO app1, today announced significant results of an eight-hospital, three-month study in Spain focused on prostate cancer patients (mHSPC, mCRPC, nmPC) undergoing systemic therapy. 

In the PRO-WAVE1 study, patients engaged with the Wave Health App over a 13-week period: Each week, patients completed a validated weekly symptom review (WSR) assessing 16 Prostate cancer-specific symptoms, including severity and/or frequency of each symptom.  A report summary of the patients’ WSR was generated for care team view in the Wave Health Connect platform – specifically to conduct weekly check ins on patients, including verifying patient completion; evaluating report content; indicating plans for follow up with each patient; and rating their perceived value of the platform. 

Care teams, including nurse coordinators and treating physicians, recognized the platform as a significant asset in patient care.  The study also reported exceptionally high compliance rates, app acceptability, and perceived value among patients.  Moreover, demographic information collected revealed a significant portion of study patients were aged 70 years or older (48%), reported a maximum educational background of high school or below (52%), and initially rated themselves with low tech confidence in their ability to use app technology (29%). Key findings accepted for poster presentation at the 2024 ASCO GU Symposium included:


  • 98% of HCPs rated the platform as useful – with the majority willing to recommend it to their peers and future patients.
  • 90% perceived platform impact on the quality of communication with patients
  • 85% perceived platform impact on addressing the number of emerging patient issues


  • 93% overall patient compliance – with 82% of patients exhibiting perfect or high compliance.
  • 93% patient satisfaction with the platform – with 100% of respondents feeling the information provided in the app was relevant to their personal circumstance.
  • 84% patient acceptance of the app – with 67% of patients using it all 13 weeks of the study.
  • Positive relationship observed between app usage and emotional wellbeing (EWB) – with the top 25% of active users experiencing astatistically significant increase in mean EWB subscores.

While the study did not focus on interventional opportunities, it uncovered multiple progressing adverse events, from Thrombosis to bladder and mental health issues.  The use of the WSR check-in process highlighted these arising issues promptly, enabled care providers to address and mitigate these potential adverse events proactively.

TTI CEO, Matt Lashey said: “The results showcase a powerful opportunity to empower patients and HCPs with actionable insights.  The majority of patients felt the app helped them update their medical team; This is only achievable with a tool that is extremely accessible and intuitive.  And for care teams, the data showcases a pathway to better manage treatment journeys in terms of overall workload and proactively handling adverse events – which drives the majority of cost and time.” 

Lashey added: “Beyond better communications and identifying risks, it was exciting to also see the impact on quality of life, whereby the patients who used the app the most, on average, experienced an improvement in emotional wellbeing over the course of the study. There is also very rich secondary data that provides opportunities for corollary analysis – for example, comparing the distribution of patient reported symptom frequency and severity across different therapies.”

Dr. Estefania Linares, a lead investigator at the Hospital Universitario La Paz, added: “The platform is very practical and would benefit overpopulated hospitals, rural hospitals, and tele-consultations. It has shown to be a powerful platform in the clinical trial settings and maybe the most useful in departments where you’re not able to see patients frequently because of distance or the overload of patients.”

Dr. Ignacio Durán, the study primary investigator, based at Hospital Universitario Marqués de Valdecilla, IDIVAL.Santander, commented, “This study demonstrates that the Wave app and platform is very relevant for patients. It is designed to give them an extra layer of safety and care that very likely will translate into better quality of life and potentially longer survival.  We need to move forward and test this app in larger populations of patients to confirm these very promising results.”

The full abstract submitted, and poster presented at ASCO GU can be found here:


Wave Health is comprised of a leading patient app, analytics engine, and HCP Portal that takes in a diverse and unique data set to supplement clinical data with critical context and generates actionable insights to improve health and reduce costs. 

Born from a personal cancer experience, TTI built the Wave Health Platform to transform the management and understanding of chronic conditions – outside clinical settings, and is now being used by large pharma, ACOs, and government health agencies around the world to support decentralized clinical trials (DCTs), active oncology surveillance programs, enhance patient engagement, and improve adherence.


Hospital participants in the PRO-WAVE1 study included: Hospital Universitario Marques de Valdecilla; Complejo Hospitalario de Navarra; Oncológico de Donostia; Fundació Puigvert Barcelona; Hospital Universitario La Paz; Hospital Universitario Virgen del Rocío; Hospital de la Sta. Creu i Sant Pau; and Hospital Universitarios Cruces.

1 Evaluation of Mobile Health Applications to Track Patient-Reported Outcomes for Oncology Patients: A Systematic Review (Jan 2021).